Австралия - английски - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; polysorbate 80; crospovidone; purified talc; macrogol 6000; magnesium stearate; povidone; colloidal anhydrous silica; hypromellose - the treatment of chronic cholestatic liver diseases

Австралия - английски - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: maize starch; colloidal anhydrous silica; pregelatinised maize starch; magnesium stearate; titanium dioxide; gelatin; sodium lauryl sulfate; sorbitan monolaurate - ursosan is indicated in the treatment of chronic cholestatic liver diseases.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; titanium dioxide; maize starch; gelatin; sodium lauryl sulfate; magnesium stearate; purified water - the treatment of chronic cholestatic liver diseases.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; purified water; maize starch; titanium dioxide; magnesium stearate; gelatin; colloidal anhydrous silica - the treatment of chronic cholestatic liver diseases.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ursodeoxycholic acid 250mg;  ;   - capsule - 250 mg - active: ursodeoxycholic acid 250mg     excipient: capsugel white op colloidal silicon dioxide magnesium stearate maize starch pregelatinised maize starch - ursosan is indicated in the treatment of chronic cholestatic liver diseases, including primary biliary cirrhosis (pbc) and primary sclerosing cholangitis (psc). in primary biliary cirrhosis ursodeoxycholic acid improves liver enzymes and igm and prevents worsening of liver histology in patients with less advanced forms of the disease, i.e. serum bilirubin less that 2 mg/dl and histologic changes in liver confined to the portal regions. prevention of complications of chronic liver disease has not been established.

Израел - английски - Ministry of Health

cts chemical industries ltd, israel - ursodeoxycholic acid - tablets - ursodeoxycholic acid 100 mg - ursodeoxycholic acid - ursodeoxycholic acid - dissolution or reductin in size of radiolucent cholesterol in patient with a functioning gallbladder. treatment of chronic liver diseases including primary billiary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia, chronic hepatitis, and alcohol cirrhosis.

Израел - английски - Ministry of Health

cts chemical industries ltd, israel - ursodeoxycholic acid - tablets - ursodeoxycholic acid 300 mg - ursodeoxycholic acid - ursodeoxycholic acid - dissolution or reduction in size of radiolucent cholesterol gallstones in patients with a functioning gallbladder. treatment of chronic liver diseases including primary biliary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia chronic hepatitis and alcoholic cirrhosis.

Ирландия - английски - HPRA (Health Products Regulatory Authority)

auden mckenzie (pharma division) ltd - ursodeoxycholic acid - tablets - 150 milligram - bile acid preparations

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

artex limited - chenodeoxycholic acid 125mg - capsule - 125 mg - active: chenodeoxycholic acid 125mg

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - chenodeoxycholic acid 250mg - tablet - 250 mg - active: chenodeoxycholic acid 250mg